Skip to main content
. 2024 Feb 3;51(3):227–242. doi: 10.1007/s10928-023-09898-0

Fig. 2.

Fig. 2

Mean dose-normalized balovaptan PK profiles after the first dose (left column) and at steady state, observed in neurotypical adults (lower row), and in adult (upper row) and pediatric (middle row) participants with ASD. Mean of at least three observed concentration values, divided by dose, are presented by nominal time points